Characteristics of the study group
Characteristic . | No. . |
|---|---|
| Age, y, median (range) | 60 (2-84) |
| Male sex (%) | 27 (56) |
| Diagnosis (%) | |
| AML | 35 (73) |
| Untreated | 5 |
| Refractory or relapsed | 30 |
| First CR | |
| Less than 12 mo | 28 |
| More than 12 mo | 2 |
| Salvage number, 30 patients | |
| First | 13 |
| Second or more | 17 |
| MDS (%) | 7 (14) |
| IPSS intermediate 1 | 2 |
| IPSS intermediate 2 | 1 |
| IPSS high | 4 |
| Untreated | 2 |
| Refractory or relapsed* | 5 |
| ALL (%) | 1 (2) |
| CML (%) | 5 (10) |
| Chronic | 1 |
| Accelerated | 1 |
| Blastic | 3 |
| Karyotype (%)† | |
| Good, Inv16; t(8;21) | 2 (5) |
| Intermediate, normal | 12 (29) |
| Poor, chromosome 11q23, 5 or 7 anomalies, others | 28 (67) |
| No. of prior regimens, AML or MDS, median (range) | 2 (0-11) |
Characteristic . | No. . |
|---|---|
| Age, y, median (range) | 60 (2-84) |
| Male sex (%) | 27 (56) |
| Diagnosis (%) | |
| AML | 35 (73) |
| Untreated | 5 |
| Refractory or relapsed | 30 |
| First CR | |
| Less than 12 mo | 28 |
| More than 12 mo | 2 |
| Salvage number, 30 patients | |
| First | 13 |
| Second or more | 17 |
| MDS (%) | 7 (14) |
| IPSS intermediate 1 | 2 |
| IPSS intermediate 2 | 1 |
| IPSS high | 4 |
| Untreated | 2 |
| Refractory or relapsed* | 5 |
| ALL (%) | 1 (2) |
| CML (%) | 5 (10) |
| Chronic | 1 |
| Accelerated | 1 |
| Blastic | 3 |
| Karyotype (%)† | |
| Good, Inv16; t(8;21) | 2 (5) |
| Intermediate, normal | 12 (29) |
| Poor, chromosome 11q23, 5 or 7 anomalies, others | 28 (67) |
| No. of prior regimens, AML or MDS, median (range) | 2 (0-11) |